Plasminogen activator inhibitor 1 (PAI-1) level and lung function over 30 years: the CARDIA study

Methods We included 996 randomly sampled participants and an additional 197 subjects with obesity from the Coronary Artery Risk Development in Young Adults cohort, recruited at a mean age of 25 years and followed for 30 years. Conclusions Generally healthy subjects with higher PAI-1 were more likely...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 141; no. 2; p. AB113
Main Authors Sherenian, Michael G., Cuttica, Michael J., Khan, Sadiya S., Colangelo, Laura A., Cook-Mills, Joan, Cho, Seong Ho, Fornage, Myriam, Gross, Myron, Jacobs, David, Schreiner, Pamela, Vaughn, Douglas, Lloyd-Jones, Donald, Kalhan, Ravi, Kumar, Rajesh
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2018
Elsevier Limited
Subjects
Coronary artery
Emphysema
Plasminogen activator inhibitors
Respiratory function
Online AccessGet full text
ISSN0091-6749
1097-6825
DOI10.1016/j.jaci.2017.12.359

Cover

More Information
Summary:Methods We included 996 randomly sampled participants and an additional 197 subjects with obesity from the Coronary Artery Risk Development in Young Adults cohort, recruited at a mean age of 25 years and followed for 30 years. Conclusions Generally healthy subjects with higher PAI-1 were more likely to have greater lung function decline over 30 years, but did not have higher odds of COPD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.12.359